vTv Therapeutics (VTVT) Equity Average (2015 - 2026)

vTv Therapeutics has disclosed Equity Average across 12 years of filings, most recently posting $77.2 million for Q1 2026.

• Equity Average for Q1 2026 came in at $77.2 million, up 565.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $77.2 million (up 565.56% YoY), and the FY2025 annual result was $39.4 million, up 858.63% from the prior year.
• Equity Average came in at $77.2 million for Q1 2026 at vTv Therapeutics, up from $67.5 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $77.2 million in Q1 2026 to a low of -$25.3 million in Q3 2023.
• The 5-year median for Equity Average is $653500.0 (2024), against an average of $7.5 million.
• Across the five-year window, Equity Average tumbled 167.62% in 2023 and jumped 1674.9% in 2025, its largest moves.
• vTv Therapeutics' Equity Average stood at -$13.7 million in 2022, then tumbled by 82.77% to -$25.0 million in 2023, then jumped by 164.54% to $16.1 million in 2024, then surged by 319.01% to $67.5 million in 2025, then rose by 14.38% to $77.2 million in 2026.
• The last three Equity Average figures came in at $77.2 million (Q1 2026), $67.5 million (Q4 2025), and $36.5 million (Q3 2025), per Business Quant data.